ARDM Aradigm Corporation

+0.1039  (8%)
Previous Close 1.29
Open 1.35
Price To book 0.00
Market Cap 20.63M
Shares 14,800,000
Volume 63,701
Short Ratio 1.44
Av. Daily Volume 61,773

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approval granted July 16, 2009.
Phase 3 data released December 1, 2016. One of two trials met primary endpoint.
Pulmaquin - ORBIT-3 and ORBIT-4
Non-cystic fibrosis bronchiectasis (non-CF BE).

Latest News

  1. Aradigm reports 1Q loss
  2. Aradigm Announces First Quarter 2017 Financial Results
  3. Aradigm Announces Fourth Quarter 2016 and Full Year Financial Results
  4. Aradigm to Present at the Biotechnology Industry Organization (BIO) CEO & Investor Conference 2017 on February 13
  5. Aradigm to Present at 9th Annual Biotech Showcase Conference on January 9
  6. Aradigm Lung Infection Antibiotic Fails Trial (ARDM)
  7. Don’t Write Off Aradigm Corporation (ARDM) Just Yet
  8. Aradigm Shares Plunge After Releasing Mixed Clinical Trial Results For Pulmaquin
  9. Aradigm posts mixed late-stage data on inhaled antibiotic
  10. Aradigm Announces Top-Line Results from Two Phase 3 Studies Evaluating Pulmaquin for the Chronic Treatment of Non-Cystic Fibrosis Bronchiectasis Patients with Lung Infections with Pseudomonas aeruginosa
  11. Aradigm Corp. :ARDM-US: Earnings Analysis: Q3, 2016 By the Numbers : November 10, 2016
  12. Aradigm to Present at the Stifel 2016 Healthcare Conference on November 16
  13. Aradigm Announces Third Quarter 2016 Financial Results
  14. Multi-million Dollar DTRA Funding for Biodefense Research with Aradigm’s Inhaled Ciprofloxacin
  15. Aradigm Announces Australian Research Council Funding to Develop Nanotechnologies Targeting Bacterial and Fungal Biofilms
  16. Aradigm Announces Last Patient Dosing Visit in ORBIT-3 and ORBIT-4 Phase 3 Studies of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis Patients
  17. Aradigm to Host Analyst Meeting and Webcast on September 26 in New York City